Anthocyanin complex exerts anti-cholangiocarcinoma activities and improves the efficacy of drug treatment in a gemcitabine-resistant cell line

KITTI INTUYOD$^{1,2}$, AROONSRI PRIPREM$^3$, CHAWALIT PAIROIKUL$^{2,4}$, CHARIYA HAHNVAJANAWONG$^{2,5,6}$, KULTHIDA VAETEEWOOTTACHARN$^{2,7}$, PORNTIP PINLAOR$^{2,8}$ and SOMCHAI PINLAOR$^{2,9}$

$^1$Biomedical Science Program, Graduate School; $^2$Cholangiocarcinoma Research Institute, Faculty of Medicine; $^3$Department of Pharmaceutical Technology, Faculty of Pharmaceutical Science; Departments of $^4$Pathology and $^5$Microbiology; $^6$Center for Excellence for Innovation in Chemistry; $^7$Department of Biochemistry, Faculty of Medicine; $^8$Centre for Research and Development in Medical Diagnostic Laboratory, Faculty of Associated Medical Sciences; $^9$Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand

Received August 7, 2017; Accepted March 1, 2018

DOI: 10.3892/ijo.2018.4306

Abstract. Cholangiocarcinoma (CCA) is a deleterious bile duct tumor with poor prognosis and is relatively resistant to chemotherapy. Therefore, alternative or supplementary agents with anticancer and chemosensitizing activities may be useful for the treatment of CCA. A novel anthocyanin complex (AC) nanoparticle, developed from extracts of cobs of purple waxy corn and petals of blue butterfly pea, has exhibited chemopreventive potential in vivo. In the present study, the anti-CCA activities of AC and their underlying molecular mechanisms were investigated further in vitro using a CCA cell line (KKU213). The potential use of AC as a chemosensitizer was also evaluated in a gemcitabine-resistant CCA cell line (KKU214GemR). It was demonstrated that AC treatment suppressed proliferation of KKU213 CCA cells in dose- and time-dependent manners. AC treatment also induced apoptosis and mitochondrial superoxide production, decreased clonogenicity of CCA cells, and downregulated forkhead box protein M1 (FOXM1), nuclear factor-κB (NF-κB) and pro-survival protein B-cell lymphoma-2 (Bcl-2). The expression of endoplasmic reticulum (ER) stress-response proteins, including protein kinase RNA-like ER kinase, phosphorylated eIF2α, eukaryotic initiation factor 2α and activating transcription factor 4, also decreased following AC treatment. It was also identified that AC treatment inhibited KKU214GemR cell proliferation in dose- and time-dependent manners. Co-treatment of KKU214GemR cells with low doses of AC together with gemcitabine significantly enhanced efficacy of the latter against this cell line. Therefore, it is suggested that AC treatment is cytotoxic to KKU213 cells, possibly via downregulation of FOXM1, NF-κB, Bcl-2 and the ER stress response, and by induction of mitochondrial superoxide production. AC also sensitizes KKU214GemR to gemcitabine treatment, which may have potential for overcoming drug resistance of CCA.

Introduction

Cholangiocarcinoma (CCA) is a bile-duct tumor that is rare in the majority of countries (1,2), but which has a far greater incidence in the Greater Mekong sub-region of southeast Asia, particularly in northeastern Thailand, where the prevalence of the small human liver fluke Opisthorchis viverrini is high (3). O. viverrini is classified as a group I carcinogen by the International Agency for Research on Cancer (4). Infection with this fluke causes chronic inflammation, leading to periductal fibrosis and ultimately contributing to the development of CCA (5,6). In northeastern Thailand, CCA is the major primary liver cancer, with its management costing US$120 million annually (5,7). Clinical presentation is typically observed at a late stage and therefore the majority of patients with CCA cannot be cured by surgical resection (8,9). Furthermore, the disease is able to develop resistance to standard chemotherapeutic drugs over time (10). Therefore, using phytochemicals with anti-inflammatory and anticancer
activities to treat cancer or to enhance the efficacy of other chemotherapeutic drugs, may be an alternative approach for the management of CCA and help to avoid drug-resistance (11-13).

Anthocyanins are the water-soluble flavonoids responsible for the blue, purple and red colors in a number of fruits, flowers and leaves (14). Anthocyanins exhibit anti-inflammatory, antiangiogenesis, antioxidant and anti-proliferative effects, and thus have a number of medical applications (15-18). Among these are prevention and treatment of cancer (19,20). Previous studies have demonstrated that the consumption of anthocyanin-rich foods is associated with a decreased risk of chronic diseases, including cardiovascular disease, arthritis and diabetes mellitus, and development of esophageal, colon, lung and skin cancers (17,21).

Cyanidin and delphinidin glycosides are the most abundant and well-studied anthocyanins with potential anticancer activity (22-24). However, a major obstacle in the use of anthocyanins is that they are unstable and prone to degradation (25). Previously, cyanidin and delphinidin were isolated from cobs of purple waxy corn (Zea mays L. var. ceritina Kulesh) and petals of blue butterfly pea (Clitoria ternatea L.) and were manipulated to form a complex with turmeric extract and other trace elements (26) to increase their stability and activity. This novel anthocyanin complex (AC) nanoparticle exhibited anti-inflammatory and anti-fibrotic effects in an O. viverinini-infected hamster model, establishing its potential for chemoprevention of CCA (26). However, the utility for CCA treatment has not yet been investigated.

The aim of the present study was to demonstrate the application of AC for CCA treatment. Anticancer activities of AC and the potential underlying molecular mechanisms against CCA were investigated in vitro using a CCA cell line. The effect of combined treatment of AC and gemcitabine against the gemcitabine-resistant CCA cell line (KKU214GemR) was also investigated. The results of the present study provide an insight into the promising use of AC phytochemical products for the treatment of CCA.

Materials and methods

Chemicals and reagents. AC was prepared as described previously (26). In brief, aqueous extracts of purple waxy corn cobs and blue butterfly pea petals were mixed with turmeric (Curcuma longa) extract (7;2:1) in the presence of 100 mM caffeic acid and pipeline (Sigma Aldrich; Merck KGaA, Darmstadt, Germany) and 2 mM zinc sulfate (Ajax Finechem; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Thereafter, the mixture was cooled and dried to yield of AC. Only one batch of AC was used throughout the present study to avoid batch-to-batch variation. Dulbecco's modified Eagle's medium (DMEM), penicillin/streptomycin, trypsin-EDTA and fetal bovine serum (FBS) were purchased from Gibco; Thermo Fisher Scientific, Inc. 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), dimethyl sulfoxide (DMSO), sulforhodamine B (SRB) and the broad-spectrum caspase inhibitor quinolone-Val-Asp-difluorophenoxymethyl ketone (Q-VD-OPh) were purchased from Sigma-Aldrich; Merck KGaA. Rabbit anti-protein kinase RNA-like endoplasmic reticulum (ER) kinase (PERK; cat. no. 5683), anti-p65 (cat. no. 8242), anti-activating transcription factor 4 (ATF4; cat. no. 11815), anti-phosphorylated eukaryotic initiation factor 2α (p-eIF2α; cat. no. 3398) (Ser51), anti-eIF2α (cat. no. 9722), anti-poly(ADP-ribose) polymerase (PARP; cat. no. 9542), anti-B-cell lymphoma-2 (Bcl-2; cat. no. 2872), anti-caspase-3 (cat. no. 9662) and anti-β-tubulin (cat. no. 2128) and radioimmunoprecipitation assay (RIPA) buffer were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Rabbit anti-forkhead box M1 (FOXM1; cat. no. sc-502) (C-20) was obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (cat. no. 111-035-003) secondary antibody was purchased from Jackson ImmunoResearch, Inc. (West Grove, PA, USA). A dead-cell apoptosis kit [Annexin V/providum iodide (PI)], Pierce™ bicinechonic acid (BCA) protein assay kit, Hank's balanced salt solution (HBSS) and MitoSOX™ Red mitochondrial superoxide indicator were obtained from Thermo Fisher Scientific, Inc. ECL™ Prime western blotting detection reagent and polynvinylene difluoro (PVDF) membrane were obtained from GE Healthcare (Chicago, IL, USA).

Human CCA cell lines. The KKU213 CCA cell line was established from Thai CCA patients as described previously (27). The gemcitabine-resistant CCA cell line KKU214GemR was established previously by exposure to stepwise increases in the concentration of gemcitabine as described previously (28). It should be noted that the parental line of KKU214GemR cells appears to be a KKU213 cell derivative (web.expasy.org/cellosaurus/CVCL_M264). However, due to the fact that KKU214GemR cells were induced to be a gemcitabine-resistant CCA cell line, it would not have any bearing on the results of the present study. The cell lines were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in a humidified incubator containing 10% CO2. KKU214GemR cells were cultured in the presence of gemcitabine to maintain its resistant phenotype, but were cultured in a drug-free medium for one passage prior to performing experiments.

Assessment of half-maximal inhibitory concentration (IC50) of AC. The IC50 was assessed using the SRB assay. For instance, KKU213 cells were seeded at 2,000 cells/well in flat-bottomed 96-well plates (Corning Inc., Corning, NY, USA). The following day, the cells were incubated with either DMSO (diluent control) or various concentrations of AC (100-800 µg/ml) dissolved in DMSO for 12, 24, 36 and 48 h at 37°C in a humidified incubator containing 10% CO2. Cells were fixed with ice-cold 40% trichloroacetic acid at 4°C for 1 h. Following washing three times with running tap water, 0.4% (w/v) SRB solution in 1% acetic acid was added and incubated further for 1 h at room temperature. Excess SRB solution was removed by washing with 1% acetic acid and SRB was dissolved by adding 10 mM Tris buffer. Absorbance at 492 nm was determined using an ELISA plate reader (Tecan Group Ltd., Männedorf, Switzerland). The absorbance at 492 nm of DMSO-treated cells was used as control. For KKU214GemR cells, the same procedure was performed, but the cells were treated with either single agent (300 µg/ml AC; 20 or 40 µM gemcitabine) or a combination of AC (300 µg/ml) and gemcitabine (20 or 40 µM) for 24, 48 and 72 h.
Assessment of cellular apoptosis. Cellular apoptosis was determined by Annexin V/PI staining according to the manufacturer's protocol. In brief, following trypsinization and washing with sterile PBS, ~10^6 KKU213 cells were resuspended in 1X binding buffer. Annexin V/PI solution was added prior to incubation at room temperature in the dark for 15 min. Stained cells were detected using a BD FACSCanto II flow cytometer and analyzed using BD FACSDiva software (version 6.1.3) (both from BD Biosciences, San Jose, CA, USA).

Plasmid transfection. The pCMV4-p65 plasmid was a gift from Professor Warner Greene, Gladstone Institute of Virology and Immunology, San Francisco, CA, USA (Addgene plasmid #21966). In total ~2x10^6 KKU213 cells were seeded into 10-cm cell culture dishes for 24 h, prior to transfection with pCMV4-p65 plasmid using X-tremeGENE HP (Roche Diagnostics, Basel, Switzerland), according to the manufacturer's protocol. Cells were then harvested at 24 h post-transfection for further experiments.

Clonogenic assay. CCA cells were seeded into 6-well plates at a density of 1,000 cells/well overnight prior to drug treatment. Cells were treated with different concentrations of AC (100-800 µg/ml) and incubated for 48 h at 37°C in a humidified incubator containing 10% CO_2. In the case of KKU214GemR cells, cells were treated with either a single agent (300 µg/ml AC; 20 or 40 µM gemcitabine) or a combination of AC (300 µg/ml) and gemcitabine (20 or 40 µM). The culture medium was changed every 2 days and cells were cultured for a further 14 days. Finally, cells were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet. Stained cells were dissolved with 33% acetic acid and absorbance at 620 nm was measured using an ELISA reader (Tecan Group Ltd.).

Measurement of mitochondrial superoxide production. Mitochondrial superoxide production was determined using MitoSOX Red mitochondrial superoxide indicator, according to the manufacturer's protocol. In brief, CCA cells were trypsinized, washed once and resuspended in HBSS with Ca^{2+}/Mg^{2+}. Subsequently, 4 µM MitoSOX Red solution was added and the mixture was incubated at 37°C for 30 min in the dark. CCA cells were centrifuged at 600 x g for 5 min at room temperature and washed with 1 ml HBSS/Ca^{2+}/Mg^{2+}. Finally, CCA cells were resuspended in HBSS/Ca^{2+}/Mg^{2+} and the fluorescence intensity at 575 nm was measured using a flow cytometer (BD Biosciences).

Western blot analysis. Protein was extracted from CCA cells using RIPA buffer (50 mM Tris/HCl, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS and 1 mM AEBSF) and the protein concentration was determined using the BCA assay. Subsequently, 20 µg protein was separated by SDS-PAGE (7 or 12% gels) and then transferred onto a PVDF membrane. Following blocking with 5% bovine serum albumin in Tris-buffered saline containing 0.05% Tween-20, membranes were incubated with primary antibodies against PERK, p65, ATF4, p-eIF2α (Ser 51), eIF2α, PARP, caspase-3, Bcl-2 and β-tubulin (all 1:1,000) overnight at 4°C. Following washing, membranes were incubated with secondary antibody (1:3,000) and the chemiluminescent reaction was developed using ECL™ Prime blotting detection reagent. Immunoreactivity bands were captured using the ImageQuant™ LAS4000 mini imager (GE Healthcare).

Statistical analysis. Data are expressed as the mean ± standard deviation. Student's t-test and analysis of variance and Tukey's test were performed to determine differences among experimental groups using SPSS (version 13.0; SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference. Non-linear regression analysis was performed to determine the IC_{50} values using GraphPad Prism (version 6; GraphPad Software, Inc., La Jolla, CA, USA).

Results

AC treatment inhibits proliferation and induces caspase-independent apoptosis of the CCA cell line. Inhibition of tumor growth and induction of cellular apoptosis are important modes of action of the majority of phytochemical agents. To determine whether AC exerts proliferation-inhibitory effects on CCA cells, and to determine relevant IC_{50} values, KKU213 cells were treated with various concentrations of AC. The SRB assay revealed that AC inhibited cell proliferation in this cell
line in a dose- and time-dependent manner (Fig. 1A). The proliferation of KKU213 cells was completely inhibited by treatment with 800 µg/ml AC after 48 h. Non-linear regression analysis identified that the IC₅₀ value of AC for KKU213 was 620 µg/ml (Fig. 1B).

It was subsequently investigated whether suppression of CCA cell proliferation by AC treatment is associated with induction of apoptosis. KKU213 cells were treated with 300 or 600 µg/ml AC for 24 h, and cellular apoptosis was investigated using flow cytometry (Fig. 2A). The results revealed that early (1.50±0.27% for AC300 and 10.33±0.83% for AC600) (Fig. 2B) and late (5.50±0.66% for AC300 and 56.70±6.05% for AC600) (Fig. 2C) apoptosis was significantly induced dose-dependently in AC-treated groups compared with the control group. These results indicated that AC exhibited cytotoxicity against CCA cells through the induction of cellular apoptosis. Levels of cleaved caspase-3, a protein marker for cellular apoptosis, was also assayed using western blotting. Cleaved caspase-3 was not observed in AC-treated KKU213 cells, but was detected in a gemcitabine-treated group (Fig. 3A). In addition, a pan-caspase inhibitor (Q-VD-OPh) was combined with AC treatment to test whether cell death was due to a caspase-independent pathway. A clonogenic assay demonstrated that treatment with 2 and 10 µM Q-VD-OPh, identified to prevent caspase activation (29), did not affect cell viability of the KKU213 cells (Fig. 3C). Notably, Q-VD-OPh treatment was not able to prevent cell death when combined with AC treatment (Fig. 3D and E), indicating that caspase-independent cell death was occurring in AC-treated CCA cells.

AC treatment inhibits colony formation of the CCA cell line. The clonogenic assay is the method of choice to determine cell reproductive viability (ability of cells to produce progeny or ability of a single cell to form a colony) following treatment with radiation or a cytotoxic agent (30,31). This approach was employed to determine the cytotoxic effects of AC treatment on a CCA cell line (Fig. 4A). Consistent with the results of the SRB assay, the presence of AC significantly inhibited KKU213 colony formation in a dose-dependent manner compared with the control group (P<0.0001) (Fig. 4B). This result indicated that the AC-mediated decrease in reproductive viability is one of the underlying molecular mechanisms of AC against CCA.

AC treatment induces mitochondrial superoxide production partly via suppression of Bcl-2 expression. Induction of superoxide production in mitochondria is an important event in the induction of apoptosis (32). To investigate whether induction of mitochondrial superoxide production is involved in AC-induced apoptosis of CCA cells, KKU213 cells were treated with AC, and levels of mitochondria-specific superoxide were determined using flow cytometry. Minimal superoxide production was detected in the control group; however, production was slightly increased in KKU213 cells treated with 300 µg/ml AC (Fig. 5). Treatment with 600 µg/ml AC significantly induced superoxide production in the mitochondria of KKU213 cells relative to the control group (P<0.001) (Fig. 5).

Since superoxide production may be inhibited by the anti-apoptotic Bcl-2 protein (32), the expression of Bcl-2 protein was investigated further in KKU213 CCA cells. Western blot
analysis revealed that the expression of Bcl-2 protein mirrored superoxide production. Expression of Bcl-2 protein decreased in the AC-treated group, particularly when 600 µg/ml AC was used, relative to the DMSO-treated control (Fig. 6). These results indicated that AC induced superoxide production-mediated apoptosis partly via the inhibition of Bcl-2 protein expression.

AC treatment targets pro-survival and endoplasmic reticulum stress (ER stress) response of the CCA cell line. FOXM1 and NF-κB are well-known oncogenic proteins involved in the survival of cancer cells (33,34). The expression of these proteins was determined in the CCA cell line following treatment with AC for 24 h. Western blot analysis revealed that expression of FOXM1 and the p65 subunit of NF-κB decreased in a dose-dependent manner in KKU213 cells treated with AC (Fig. 6). Notably, expression of these proteins was almost completely inhibited in KKU213 cells treated with 600 µg/ml AC compared with the DMSO-treated control (Fig. 6). Additionally, KKU213 cells were transfected with p65 plasmid DNA and the influence of p65 induction on AC treatment of KKU213 cells was determined using a clonogenic assay. The p65 subunit of NF-κB was successfully induced in KKU213 as identified using western blot analysis (Fig. 7A). However, the clonogenic assay revealed that p65 overexpression did not affect the viability of KKU213 cells compared with non-transfected and mock-transfected controls (Fig. 7B and C). This implies that AC is a potent inducer of apoptosis against CCA cells, and that induction of a pro-survival transcription factor was not able to protect CCA cells from cell death following AC treatment. A previous study has identified that AC treatment dramatically induced mitochondrial superoxide production; excessive superoxide production may cause protein misfolding and ultimately induce ER stress (35). Therefore, the expression of proteins in the PERK/eIF2α/ATF4 axis, which is an important ER stress-response pathway, was investigated. Western blot analysis revealed that expression of PERK, p-eIF2α (Ser51) and ATF4 in KKU213 cells decreased following AC treatment (Fig. 6). Notably, total eIF2α expression was not affected by AC treatment, suggesting that AC suppresses phosphorylation of the eIF2α protein. In addition to FOXM1, p65 and the PERK/eIF2α/ATF4 axis, it was identified that PARP expression was also suppressed by AC treatment, particularly at the highest dose used (Fig. 6).

AC treatment increases gemcitabine sensitivity of the gemcitabine-resistant KKU214GemR CCA cell line. Resistance to chemotherapeutic treatment is an important obstacle for the treatment of various types of cancer, including CCA (36). Therefore, whether co-treatment with AC was able to enhance the effect of gemcitabine was investigated. The SRB assay revealed that the IC50 of gemcitabine against the KKU214GemR CCA cell line was 32.11 µM at 72 h, whereas the IC50 of gemcitabine against the parental KKU214 cell line was 0.40 µM at 72 h (data not shown), agreeing with a previous study (28). Treatment of KKU214GemR cells with AC inhibited cell proliferation in a dose- and time-dependent manner (Fig. 8A). For gemcitabine treatment alone, KKU214GemR cell proliferation was markedly inhibited by treatment with 40 µM for 72 h (Fig. 8B). AC at a dose of 300 µg/ml, which did not exert a proliferation-inhibitory effect on KKU214GemR cells, was selected for co-treatment with 20 or 40 µM gemcitabine. As expected, the two combinations significantly enhanced gemcitabine-mediated proliferation inhibition compared with treatments with single agents (P<0.01 for 20 µM gemcitabine vs. 300 µg/ml AC+20 µM gemcitabine; P<0.001 for 40 µM gemcitabine vs. 300 µg/ml AC+40 µM gemcitabine) (Fig. 8C). Furthermore, the clonogenic assay also identified a significant enhancement of gemcitabine treatment when co-treated with AC (P<0.05) (Fig. 8D). Annexin V/PI
staining coupled with flow cytometry was used to detect apoptotic cells following combination treatment of KKU214\textsuperscript{GemR} cells. Administration of AC (300 µg/ml) and gemcitabine (40 µM) significantly induced early apoptosis of these cells compared with single treatments and the control group (\(P<0.0001\)) (Fig. 9). These results indicated that AC treatment...
significantly enhanced the efficacy of gemcitabine against the gemcitabine-resistant KKU214GemR cell line.

**Discussion**

Several previous studies have demonstrated that anthocyanins exert anticancer activity against various types of cancer, including HCC, melanoma, colon cancer, lung cancer and breast cancer (37-39). In our previous study, we developed a novel AC, which primarily consisted of extracts of purple corn cobs, blue butterfly peas and turmeric (26). The combination of these exhibited increased antioxidant activity and increased thermal stability compared with that of individual extracts (26). In the present study, to the best of our knowledge, we have identified, for the first time, anti-CCA activity of AC, which exhibited cytotoxicity against a CCA cell line through the suppression of cell proliferation and induction of caspase-independent apoptosis probably via increased mitochondrial superoxide production. Furthermore, AC also suppressed the expression of a number of oncogenic proteins that have previously been reported to be upregulated in CCA, including FOXM1, NF-κB and ER stress-response proteins. The potential underlying molecular mechanisms of AC treatment on CCA cells are summarized in Fig. 10. AC was able to potentiate gemcitabine treatment against the gemcitabine-resistant KKU214GemR cell line. We therefore hypothesize that AC has a potential function as an alternative or supplementary treatment for CCA.

cDNA analysis of *O. viverrini*-associated CCA clinical samples revealed that FOXM1 was highly expressed, being the second most abundant gene in these samples (40). FOXM1 has been implicated primarily in cell proliferation and survival, as well as in cancer progression (34). In the present study, suppression of cell proliferation and induction of cellular apoptosis following AC treatment were observed alongside downregulation of FOXM1 expression. These results suggest that suppression of FOXM1 is, in part, the mode of action of AC against CCA. To the best of our knowledge, the present study is the first to identify the effects of cyanidin and delphinidin on FOXM1 expression. However, a previous study demonstrated that curcumin, an important bioactive compound in turmeric extract, was able to suppress FOXM1 (41). Therefore, suppression of FOXM1 using AC treatment is potentially mediated by either anthocyanin(s) (cyanidin and/or delphinidin) or turmeric extract or both. In addition to FOXM1, western blot analysis also demonstrated the downregulation of NF-κB in AC-treated CCA cells. NF-κB is a well-known transcription factor associated with inflammation and cancer (42-44). A previous study has identified that NF-κB, particularly its p65 subunit, was overexpressed in *O. viverrini*-associated CCA tumor tissues. Furthermore, treatment with dehydroxymenthylepoxyquinomicin inhibited CCA cell proliferation and induced apoptosis.
in KKU213 cells via the suppression of NF-κB and Bcl-2 proteins (45). The results of the present study are in general agreement with this previous study, demonstrating that the p65 subunit of NF-κB and Bcl-2 were also suppressed concurrently with induction of apoptosis in the AC-treated KKU213 CCA cell line. Cyanidin and delphinidin are known to suppress the expression of NF-κB and Bcl-2 (46,47). Furthermore, the turmeric extract in AC was also identified to suppress NF-κB and Bcl-2 (48,49). Therefore, we hypothesized that cyanidin, delphinidin and turmeric extract in AC may synergistically inhibit NF-κB and Bcl-2. Curcumin, an important active ingredient in turmeric extract, is able to inhibit NF-κB expression and induce cancer cell apoptosis. AC, composed of purple corn cob, blue butterfly pea and turmeric extracts at a ratio of 7:2:1, contains ~60 µg turmeric extract per 600 µg/ml AC. In its standard form, turmeric contains 5% curcumin, implying that there is ~3 µg or 8 µM curcumin in 60 µg turmeric extract. In our previous study, we identified that significant suppression of proliferation, induction of apoptosis (4% of the cell population compared with the untreated control) and suppression of pro-survival proteins in the KKU213 cell line were only observed when treated with 50 µM curcumin (49). The synergistic effect of combining different anthocyanins was also demonstrated previously (50,51). These results support our hypothesis that the cytotoxicity of AC against CCA cells is mediated by synergism of cyanidin, delphinidin and turmeric extract. Notably, in the present study, the function of p65 on AC treatment of KKU213 cells was also determined using p65 plasmid DNA transfection coupled with a clonogenic assay. Although p65 was successfully induced in KKU213 cells, the clonogenic assay revealed that

Figure 8. AC treatment sensitizes the KKU214GemR cell line to gemcitabine treatment. KKU214GemR cells were seeded in 96-well plates and treated with either (A) AC alone or (B) gemcitabine alone at indicated times. (C) Cells were treated with either the single agent (AC or gemcitabine) or a combination of AC (300 µg/ml) and gemcitabine (20 or 40 µM) for 72 h. The percentage of cell proliferation (relative to control) was determined using the SRB assay. Inhibition of cell proliferation was observed in the combination treatment compared with treatment with either agent alone. (D) Effect of combined treatment on colony formation of KKU214GemR cells was also determined using the clonogenic assay. The relative difference in colony formation of KKU214GemR cells was investigated by dissolving stained colonies with 33% acetic acid and absorbance at the OD at 620 nm was determined using an ELISA reader. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. AC, anthocyanin complex; Gem, gemcitabine; OD, optical density.
induction of pro-survival transcription factor expression was not able to protect KKU213 cells from apoptosis following AC treatment. Failure of NF-κB to prevent cell death has also been demonstrated in tumor necrosis factor α-induced apoptosis in the HeLa cell line (52). Furthermore, failure to escape apoptosis following p65 induction may be because AC treatment induces CCA cell apoptosis through multiple pathways. Therefore, AC is a potent apoptosis inducer against CCA cells.

AC treatment also markedly induced superoxide production from mitochondria in KKU213 cells. Mitochondrial superoxide has been demonstrated as an inducer of apoptosis (32). Apoptosis induced in this manner is consistent with a previous

Figure 9. Combination of AC and gemcitabine treatment induces early apoptosis of the KKU214GemR cell line. KKU214GemR cells were treated with (A) 0.1% dimethyl sulfoxide, (B) AC (300 µg/ml) or (C) gemcitabine (40 µM), or (D) a combination of AC (300 µg/ml) and gemcitabine (40 µM) for 72 h. Apoptotic cells were stained with Annexin V-FITC/PI solution and analyzed using flow cytometry. (E) The percentage of cells undergoing early apoptosis was calculated from three independent experiments. *P<0.05 and ****P<0.0001. AC, anthocyanin complex; FITC, fluorescein isothiocyanate; PI, propidium iodide; Gem, gemcitabine.

Figure 10. Schematic diagram of the postulated mechanism of AC against CCA cell lines. AC treatment downregulates FOXM1 and NF-κB expression, leading to suppression of Bcl-2 expression. AC treatment also stimulates superoxide production from mitochondria, in part due to Bcl-2 suppression, since this protein serves a function in inhibiting superoxide production from mitochondria. Massive superoxide production leads to DNA damage. Inhibition of the DNA damage-repair protein PARP by AC treatment may induce DNA damage-mediated apoptosis. In addition to DNA damage, superoxide production may result in the induction of protein misfolding or of unfolded proteins, accumulation of which stimulates the UPR in the ER. AC treatment inhibits the primary UPR pathway (PERK/eIF2α/ATF4), leading to ER stress and induction of apoptosis. AC, anthocyanin complex; CCA, cholangiocarcinoma; FOXM1, forkhead box M1; NF-κB, nuclear factor-κB; Bcl-2, B-cell lymphoma-2; PARP, poly(ADP-ribose) polymerase; UPR, unfolded protein response; ER, endoplasmic reticulum; PERK, protein kinase RNA-like ER kinase; eIF2α, eukaryotic initiation factor 2α; ATF4, activating transcription factor 4.
It was identified that KKU214GemR cells were ~80-fold more resistant to gemcitabine compared with its parental cell line. However, the combination of AC with gemcitabine significantly enhanced the efficacy of gemcitabine against KKU214GemR cells compared with single agent treatment. Although the potential of AC against a CCA cell line as well as its potential as a chemosensitizer in a gemcitabine-resistant CCA cell line have been demonstrated in the present study, these results have not been verified in an animal model of CCA. Therefore, the anticancer activity of AC should be investigated further in xenograft mouse or liver fluke-induced hamster CCA models. Furthermore, the anticancer potential of AC requires testing in diverse cancer cell types to support its potential use as an alternative or supplementary treatment for cancer, particularly CCA. Additionally, high-throughput approaches, including RNA sequencing, are required to explore the precise mechanisms underlying anticancer and chemosensitization activities of AC.

In conclusion, the results of the present study demonstrated that AC possesses cytotoxicity against CCA cell lines by suppression of cell proliferation and induction of caspase-independent apoptosis possibly via downregulation of FOXM1, NF-κB and the ER stress response, and by induction of mitochondrial superoxide production. AC also sensitizes KKU214GemR cells to gemcitabine treatment. Therefore, AC has potential as an alternative treatment agent and may assist in overcoming drug resistance of CCA when co-administered with other chemotherapeutic agents.

Acknowledgements

The authors thank Miss Sucharat Limsitthichaikoon for assisting with AC preparation and the Research Instrument Unit, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, for technical and facility support.

Funding

This study was supported in part by the Thailand Research Fund (TRF) and Khon Kaen University through Royal Golden Jubilee PhD joint funding program (grant no. PHD/0166/2553) and also by the TRF and Medical Research Council (MRC) UK via TRF-MRC Joint Health Research (grant no. DBG5980004) and Khon Kaen University Research Fund (grant no. KKU600701).

Availability of data and materials

The data sets generated during the study are available from the corresponding author on reasonable request.

Authors’ contributions

SP and KI mainly designed, performed the research and wrote the manuscript. KI analyzed the data, and AP, CP, CH, KV and PP helped to prepare and provided materials, and analyzed the data. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References